|
BRPI0716092A2
(pt)
*
|
2006-08-30 |
2013-09-17 |
Celgene Corp |
composto ou um sal, solvato, ou estereoisâmero do mesmo, composiÇço farmacÊutica, mÉtodo para tratar, controlar ou prevenir uma doenÇa ou distérbio, e, forma de dosagem de unidade simples.
|
|
CL2007002499A1
(es)
|
2006-08-30 |
2008-03-14 |
Phenomix Corp |
Sales citrato y tartrato de compuestos derivados de acido pirrolidinilaminoacetilpirrolidinboronico, inhibidores de dpp-iv; metodo de preparacion; forma solida; combinacion farmaceutica, util para el tratamiento de diabetes.
|
|
US8877780B2
(en)
|
2006-08-30 |
2014-11-04 |
Celgene Corporation |
5-substituted isoindoline compounds
|
|
NZ592425A
(en)
*
|
2008-10-29 |
2013-04-26 |
Celgene Corp |
Isoindoline compounds for use in the treatment of cancer
|
|
WO2012135299A1
(en)
|
2011-03-28 |
2012-10-04 |
Deuteria Pharmaceuticals Inc |
2',6'-dioxo-3'-deutero-piperdin-3-yl-isoindoline compounds
|
|
EP2943201B2
(en)
|
2013-01-14 |
2020-07-29 |
Deuterx, LLC |
3-(5-substituted-4-oxoquinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
|
WO2014152833A1
(en)
|
2013-03-14 |
2014-09-25 |
Deuterx, Llc |
3-(substituted-4-oxo-quinazolin-3(4h)-yl)-3-deutero-piperidine-2,6-dione derivatives
|
|
UA117141C2
(uk)
|
2013-10-08 |
2018-06-25 |
Селджин Корпорейшн |
Склади (s)-3-(4-((4-(морфолінометил)бензил)оксі)-1-оксоізоіндолін-2-іл)піперидин-2,6-діону
|
|
CA2932120C
(en)
|
2013-12-06 |
2023-09-19 |
Celgene Corporation |
Methods for determining drug efficacy for the treatment of diffuse large b-cell lymphoma, multiple myeloma, and myeloid cancers
|
|
US20180228907A1
(en)
|
2014-04-14 |
2018-08-16 |
Arvinas, Inc. |
Cereblon ligands and bifunctional compounds comprising the same
|
|
KR20250127179A
(ko)
*
|
2014-04-14 |
2025-08-26 |
아비나스 오퍼레이션스, 인코포레이티드 |
단백질분해의 이미드-기초된 조절인자 및 연관된 이용 방법
|
|
US9499514B2
(en)
*
|
2014-07-11 |
2016-11-22 |
Celgene Corporation |
Antiproliferative compounds and methods of use thereof
|
|
US20180267043A1
(en)
*
|
2014-10-07 |
2018-09-20 |
Celgene Corporation |
Use of biomarkers for predicting clinical sensitivity to cancer treatment
|
|
WO2016105518A1
(en)
*
|
2014-12-23 |
2016-06-30 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
US9694084B2
(en)
|
2014-12-23 |
2017-07-04 |
Dana-Farber Cancer Institute, Inc. |
Methods to induce targeted protein degradation through bifunctional molecules
|
|
KR102564925B1
(ko)
|
2015-01-20 |
2023-08-07 |
아비나스 오퍼레이션스, 인코포레이티드 |
안드로겐 수용체의 표적화된 분해를 위한 화합물 및 방법
|
|
US12312316B2
(en)
|
2015-01-20 |
2025-05-27 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of androgen receptor
|
|
EP3302482A4
(en)
|
2015-06-05 |
2018-12-19 |
Arvinas, Inc. |
Tank-binding kinase-1 protacs and associated methods of use
|
|
US9809603B1
(en)
|
2015-08-18 |
2017-11-07 |
Deuterx, Llc |
Deuterium-enriched isoindolinonyl-piperidinonyl conjugates and oxoquinazolin-3(4H)-yl-piperidinonyl conjugates and methods of treating medical disorders using same
|
|
EP3337476A4
(en)
|
2015-08-19 |
2019-09-04 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of bromodomain-containing proteins
|
|
AR107321A1
(es)
*
|
2016-01-08 |
2018-04-18 |
Celgene Corp |
Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos
|
|
US10759808B2
(en)
*
|
2016-04-06 |
2020-09-01 |
The Regents Of The University Of Michigan |
Monofunctional intermediates for ligand-dependent target protein degradation
|
|
EP3454862B1
(en)
|
2016-05-10 |
2024-09-11 |
C4 Therapeutics, Inc. |
Spirocyclic degronimers for target protein degradation
|
|
CN109641874A
(zh)
|
2016-05-10 |
2019-04-16 |
C4医药公司 |
用于靶蛋白降解的c3-碳连接的戊二酰亚胺降解决定子体
|
|
WO2017197055A1
(en)
|
2016-05-10 |
2017-11-16 |
C4 Therapeutics, Inc. |
Heterocyclic degronimers for target protein degradation
|
|
CN109790143A
(zh)
|
2016-05-10 |
2019-05-21 |
C4医药公司 |
用于靶蛋白降解的胺连接的c3-戊二酰亚胺降解决定子体
|
|
KR20250044800A
(ko)
|
2016-10-11 |
2025-04-01 |
아비나스 오퍼레이션스, 인코포레이티드 |
안드로겐 수용체의 표적 분해용 화합물 및 방법
|
|
EP3535265A4
(en)
|
2016-11-01 |
2020-07-08 |
Arvinas, Inc. |
PROTACS TARGETING ON TAU PROTEIN AND RELATED METHODS FOR USE
|
|
PL3689868T3
(pl)
|
2016-12-01 |
2024-03-11 |
Arvinas Operations, Inc. |
Pochodne tetrahydronaftalenu i tetrahydroizochinoliny jako degradery receptorów estrogenowych
|
|
WO2018118598A1
(en)
|
2016-12-23 |
2018-06-28 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of fetal liver kinase polypeptides
|
|
US11173211B2
(en)
|
2016-12-23 |
2021-11-16 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of rapidly accelerated Fibrosarcoma polypeptides
|
|
CN117510491A
(zh)
|
2016-12-23 |
2024-02-06 |
阿尔维纳斯运营股份有限公司 |
用于迅速加速性纤维肉瘤多肽的靶向降解的化合物和方法
|
|
CN110753693A
(zh)
|
2016-12-23 |
2020-02-04 |
阿尔维纳斯运营股份有限公司 |
Egfr蛋白水解靶向嵌合分子和相关使用方法
|
|
US11191741B2
(en)
|
2016-12-24 |
2021-12-07 |
Arvinas Operations, Inc. |
Compounds and methods for the targeted degradation of enhancer of zeste homolog 2 polypeptide
|
|
IL300417A
(en)
|
2017-01-26 |
2023-04-01 |
Arvinas Operations Inc |
Bifunctional benzothiophene compounds, preparations containing them and their use in therapy
|
|
CN110612294B
(zh)
|
2017-01-31 |
2024-01-16 |
阿尔维纳斯运营股份有限公司 |
人小脑蛋白配体和包含其的双官能化合物
|
|
CN110769822A
(zh)
|
2017-06-20 |
2020-02-07 |
C4医药公司 |
用于蛋白降解的n/o-连接的降解决定子和降解决定子体
|
|
CN111315735B
(zh)
|
2017-09-04 |
2024-03-08 |
C4医药公司 |
二氢苯并咪唑酮
|
|
EP3679026A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Glutarimide
|
|
EP3679028A1
(en)
|
2017-09-04 |
2020-07-15 |
C4 Therapeutics, Inc. |
Dihydroquinolinones
|
|
EP3710002A4
(en)
|
2017-11-16 |
2021-07-07 |
C4 Therapeutics, Inc. |
DEGRADATION AND DEGRADATION AGENTS FOR TARGETED PROTEIN DEGRADATION
|
|
WO2019099926A1
(en)
|
2017-11-17 |
2019-05-23 |
Arvinas, Inc. |
Compounds and methods for the targeted degradation of interleukin-1 receptor-associated kinase 4 polypeptides
|
|
US11220515B2
(en)
|
2018-01-26 |
2022-01-11 |
Yale University |
Imide-based modulators of proteolysis and associated methods of use
|
|
WO2019191112A1
(en)
|
2018-03-26 |
2019-10-03 |
C4 Therapeutics, Inc. |
Cereblon binders for the degradation of ikaros
|
|
MX2020010420A
(es)
|
2018-04-04 |
2020-12-11 |
Arvinas Operations Inc |
Moduladores de la proteólisis y métodos asociados de uso.
|
|
WO2019204354A1
(en)
|
2018-04-16 |
2019-10-24 |
C4 Therapeutics, Inc. |
Spirocyclic compounds
|
|
MX2020011183A
(es)
|
2018-04-23 |
2020-11-12 |
Celgene Corp |
Compuestos de 4-aminoisoindolina-1,3-diona sustituidos y su uso para el tratamiento de linfoma.
|
|
EP3578561A1
(en)
|
2018-06-04 |
2019-12-11 |
F. Hoffmann-La Roche AG |
Spiro compounds
|
|
CN112912376A
(zh)
|
2018-08-20 |
2021-06-04 |
阿尔维纳斯运营股份有限公司 |
用于治疗神经变性疾病的具有E3泛素连接酶结合活性并靶向α-突触核蛋白的蛋白水解靶向嵌合(PROTAC)化合物
|
|
WO2020064002A1
(zh)
|
2018-09-30 |
2020-04-02 |
中国科学院上海药物研究所 |
异吲哚啉类化合物、其制备方法、药物组合物及用途
|
|
CA3119343C
(en)
|
2018-11-13 |
2024-01-16 |
Biotheryx, Inc. |
Substituted isoindolinones
|
|
CN111285850B
(zh)
|
2018-12-06 |
2022-04-22 |
中国科学院上海药物研究所 |
一类异吲哚啉类化合物、其制备方法、药物组合物及其应用
|
|
CN120698985A
(zh)
|
2018-12-20 |
2025-09-26 |
C4医药公司 |
靶向蛋白降解
|
|
EA202192738A1
(ru)
|
2019-04-12 |
2022-03-17 |
С4 Терапьютикс, Инк. |
Трициклические соединения, обеспечивающие разрушение белка ikaros и белка aiolos
|
|
AR119057A1
(es)
|
2019-05-31 |
2021-11-17 |
Celgene Corp |
Compuestos de 1-oxo-isoindolin-5-carboxamida sustituida, composiciones de estos y métodos de tratamiento con dichos compuestos
|
|
CN119954801A
(zh)
|
2019-07-17 |
2025-05-09 |
阿尔维纳斯运营股份有限公司 |
Tau蛋白靶向化合物及相关使用方法
|
|
MX2022002415A
(es)
|
2019-08-26 |
2022-03-22 |
Arvinas Operations Inc |
Metodos de tratamiento del cancer de mama con derivados de tetrahidronaftaleno como degradadores del receptor de estrogenos.
|
|
EP4041231A1
(en)
*
|
2019-10-09 |
2022-08-17 |
Monte Rosa Therapeutics AG |
Isoindolinone compounds
|
|
CN119019369A
(zh)
|
2019-10-17 |
2024-11-26 |
阿尔维纳斯运营股份有限公司 |
含有与bcl6靶向部分连接的e3泛素连接酶结合部分的双官能分子
|
|
WO2021105335A1
(en)
|
2019-11-27 |
2021-06-03 |
Captor Therapeutics S.A. |
Piperidine-2, 6-dione derivatives which bind to cereblon, and methods of use thereof
|
|
KR20220106801A
(ko)
|
2019-11-27 |
2022-07-29 |
캡터 테라퓨틱스 에스.에이. |
세레블론에 결합하는 피페리딘-2,6-디온 유도체 및 이의 사용 방법
|
|
CN115175901B
(zh)
|
2019-12-19 |
2024-03-22 |
阿尔维纳斯运营股份有限公司 |
用于雄激素受体的靶向降解的化合物和方法
|
|
EP4146642A1
(en)
|
2020-05-09 |
2023-03-15 |
Arvinas Operations, Inc. |
Methods of manufacturing a bifunctional compound, ultrapure forms of the bifunctional compound, and dosage forms comprising the same
|
|
IL300308A
(en)
*
|
2020-08-03 |
2023-04-01 |
Captor Therapeutics S A |
Low molecular weight protein complexes and their applications
|
|
JP2023539663A
(ja)
|
2020-08-28 |
2023-09-15 |
アルビナス・オペレーションズ・インコーポレイテッド |
急速進行性線維肉腫タンパク質分解化合物及び関連する使用方法
|
|
BR112023004656A2
(pt)
|
2020-09-14 |
2023-05-09 |
Arvinas Operations Inc |
Formas cristalinas e amorfas de um composto para a degradação direcionada do receptor de estrogênio
|
|
MX2023003114A
(es)
*
|
2020-09-23 |
2023-03-23 |
St Jude Childrens Res Hospital Inc |
Analogos de n-(2-(2,6-dioxopiperidin-3-il)-1,3-dioxoisoindolin-5-i l)arilsulfonamida sustituidos como moduladores de la proteina cereblon.
|
|
WO2022146151A1
(en)
|
2020-12-30 |
2022-07-07 |
Captor Therapeutics S.A. |
Novel compounds which bind to cereblon, and methods of use thereof
|
|
MX2023008296A
(es)
|
2021-01-13 |
2023-09-29 |
Monte Rosa Therapeutics Inc |
Compuestos de isoindolinona.
|
|
WO2022200857A1
(en)
*
|
2021-03-22 |
2022-09-29 |
Monte Rosa Therapeutics Ag |
Pharmaceutical compositions for use in the prevention and treatment of a disease or disorder caused by or associated with one or more premature termination codons
|
|
WO2022221673A1
(en)
|
2021-04-16 |
2022-10-20 |
Arvinas Operations, Inc. |
Modulators of bcl6 proteolysis and associated methods of use
|
|
WO2022255889A1
(en)
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
WO2022255890A1
(en)
|
2021-06-01 |
2022-12-08 |
Captor Therapeutics S.A. |
Compounds which bind to cereblon, and use thereof
|
|
US20250346575A1
(en)
*
|
2021-11-09 |
2025-11-13 |
Korea Research Institute Of Chemical Technology |
Isoindolinone derivative having glutarimide mother nucleus, and use thereof
|
|
CA3249074A1
(en)
|
2022-06-06 |
2023-12-14 |
C4 Therapeutics, Inc. |
BICYCLIC SUBSTITUTION GLUTARIMIDE CEREBLON BINDERS
|
|
WO2024015618A2
(en)
*
|
2022-07-15 |
2024-01-18 |
St. Jude Children's Research Hospital, Inc. |
Substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione/2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione analogs as modulators of cereblon protein
|
|
WO2024054591A1
(en)
|
2022-09-07 |
2024-03-14 |
Arvinas Operations, Inc. |
Rapidly accelerated fibrosarcoma (raf) degrading compounds and associated methods of use
|
|
KR20240066904A
(ko)
*
|
2022-11-08 |
2024-05-16 |
주식회사 온코드바이오 |
아릴시클로알킬아마이드 구조를 갖는 이소인돌리논 유도체 및 이의 용도
|
|
US12448399B2
(en)
|
2023-01-26 |
2025-10-21 |
Arvinas Operations, Inc. |
Cereblon-based KRAS degrading PROTACs and uses related thereto
|
|
WO2024167423A1
(en)
|
2023-02-07 |
2024-08-15 |
Captor Therapeutics S.A. |
Gspt1 degrader compounds
|
|
KR102570883B1
(ko)
*
|
2023-04-13 |
2023-08-29 |
(주) 사이러스테라퓨틱스 |
신규한 gspt1 분해제 및 이의 용도
|
|
US12496301B2
(en)
|
2023-12-08 |
2025-12-16 |
Arvinas Operations, Inc. |
Use of androgen receptor degrader for the treatment of spinal and bulbar muscular atrophy
|